ARTICLE | Clinical News
PRO 2000: Phase II/IIb data
February 16, 2009 8:00 AM UTC
Indevus Pharmaceuticals Inc. (NASDAQ:IDEV), Lexington, Mass. Product: PRO 2000 Business: Infectious Molecular target: HIV gp120 Description: Synthetic topical vaginal microbicide derived from naphtha...